RSV Vaccine Effectiveness Against Hospitalization Among US Adults Aged 60 Years or Older During 2 Seasons

作者：Diya Surie, Wesley H. Self, Katharine A. Yuengling, Adam S. Lauring, Yuwei Zhu, Basmah Safdar, Adit A. Ginde, Samantha J. Simon, Ithan D. Peltan, Samuel M. Brown, Manjusha Gaglani, Shekhar Ghamande, Cristie Columbus, Nicholas M Mohr, Kevin W. Gibbs, David N. Hager, Matthew E. Prekker, Michelle N. Gong, Amira Mohamed, Nicholas J. Johnson, Jay S. Steingrub, Akram Khan, Abhijit Duggal, Alexandra June Gordon, Nida Qadir, Steven Y. Chang, Christopher Mallow, Jamie Felzer, Jennie H. Kwon, Matthew C. Exline, Ivana A. Vaughn, Mayur Ramesh, Leigh Papalambros, Jarrod Mosier, Estelle S. Harris, Adrienne Baughman, Sydney A. Cornelison, Paul W. Blair, Cassandra A. Johnson, Nathaniel M. Lewis, Sascha Ellington, Carlos G. Grijalva, H. Keipp Talbot, Jonathan D. Casey, Natasha Halasa, James D. Chappell, Rachel E. Rutkowski, C. Kevin, Fatimah S. Dawood, Investigating Respiratory Viruses in the Acutely Ill (IVY) Network, Kelsey N. Womack, Jillian P. Rhoads, Colleen Ratcliff, Todd W. Rice, Julio Angulo, Stacey Batey, Marcia Blair, Shanice Cummings, Abby Fink, Claudia Guevara, Rendie McHenry, Anna Jackson, Jennifer L Luther, Bryan P M Peterson, Neekar Rashid, Wanderson Rezende, Kalee E. Rumfelt, Laura Short, Bijal A. Parikh, Carleigh Samuels, Lucy Vogt, Caroline A. O’Neil, Alyssa Valencia, Francesca Yerbic, Olivia Arter, Akshay Saluja, Elianora Ovchiyan, Sachina Mensah, David McDonald, Kim Van Vu, Vasisht Srinivasan, M. Catherine Mckeon, Joshua C. Acidera, Leenay Coughlin, Dylan Clark, Catherine L. Hough, Annabelle Blue, Davika Dige, Jenny Chan, Maria Makman, C. T. Tran, Roshan Mathew, Emily Tribbet, Adrían V. Hernández, Genesis Briceño, Cameron Hypes, Karen Lutrick, Beth Salvagio Campbell, Anirudh Goyal, Uchechi Okoronkwo, Ivan Velasquez, Kimberly Manchester, Adra Yigitkanli, Harith Ali, Safa Saeed, Minh Q. Phan, Carolina Rivas, Laurynn M. Giles, Mary O’Rourke, Audrey Hendrickson, Anne Frosch, Cody Tran, Sukantha Chandrasekaran, Omai B. Garner, Riylie McBride, Bryce Bosworth, Hannah Strait, Darija Ward, Tresa McNeal, Kempapura Murthy, Leah Odame‐Bamfo, Nicole Calhoun, Jocelyn Cravens, Spencer Rose, Michael J. Smith, Catherine Raver, Robert Gottlieb, Sydney Buehrig, Priyanka Rana, Marianna Hurutado-Rodriguez, Gabriela Pérez, Lois Lamerato, Khaled Almawri, Jaskiran Bansal, Rachna Jayaprakash, Jean Ashley Lava, Alycia Lilla, Catherine McKeon, Zina Pinderi, Maria Santana-Garces, Tanisha Shack, Shruti Tirumala, Katrina Williams, Ashley Bychkowski, Symone Dunkley, T. L. Fisher, Sheila Gasparek, Daniela Gonzalez, Therissa Grefsrub, Mariana Hurutado-Rodriguez, D. Mariscal, Sarah Karow, Maryiam Khan, Gabrielle Swoope, Brooke Lee, Awais Rasul, Rushil Madan, Tyler Haley, Kristina Luikart, Amer Charif, Rasha Alrifae, Thomas Sturges, Ibrahim Hammad, C. Lang, Manish Pathak, Jun Sung Park, Connor Snyder, R. Eddie Wilson, Zachery Lewald, Anne Zepeski, Paul Nassar, Jacob Hampton, Cathy Fairfield, Heath Gibbs, Courtney Feitsam, Ike Appleton, Samantha Simon, Amanda Martinez, Amy P. Sullivan, Anna Barrow, Jacob Rademacher, Erika Alor, Yvette Evans, Laura Aguilar Marquez, J. Bassett, Shandi Poulson, Vineela Thumma, A Webber, Lauren T Vanasse, Laurence W. Busse, William S. Bender, Jennifer G. Wilson, Emily T. Martin, Aleda M. Leis · 发表于：JAMA · 年份：2025 · DOI：10.1001/jama.2025.15896 · 被引用次数：27 · 研究领域：Respiratory viral infections research、COVID-19 Clinical Research Studies、Immune responses and vaccinations

Importance: Respiratory syncytial virus (RSV) vaccines for adults aged 60 years or older became available in 2023. One dose is recommended for all adults aged 75 years or older and those aged 60 to 74 years at increased risk of severe RSV; however, duration of protection is unknown. Objective: To evaluate RSV vaccine effectiveness against RSV-associated hospitalization among adults aged 60 years or older during 2 RSV seasons. Design, Setting, and Participants: A total of 6958 adults aged 60 years or older were included in this test-negative, case-control study if they were hospitalized with acute respiratory illness at any of 26 hospitals in 20 US states during the October 1, 2023, to March 31, 2024, or October 1, 2024, to April 30, 2025, RSV seasons and had respiratory virus testing within 10 days of illness onset. Case patients tested positive for RSV only; control patients tested negative for RSV, SARS-CoV-2, and influenza. Demographic and clinical data were obtained through patient interview and electronic health records. Exposures: Receipt of 1 RSV vaccine dose at least 14 days before illness onset. Main Outcomes and Measures: Multivariable logistic regression was used to compare the odds of RSV vaccination among hospitalized cases and controls. Models were adjusted for age, sex, race and ethnicity, geographic region, and calendar month and year. Vaccine effectiveness was estimated as (1 - adjusted odds ratio) × 100%. Analyses were stratified by timing of RSV vaccine rec...